The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Drug Review Updates
Atezolizumab-Bevacizumab Non-squamous Non-Small Cell Lung Cancer
(Final Recommendation Issued as of July 3, 2020)
Niraparib (Zejula) for Ovarian Cancer
(Open for Feedback on Recommendation until July 17, 2020)